Pulmonary Arterial Hypertension Pipeline Insight Research
25 Aug 2021
Gene TherapyAntibodyOrphan DrugBreakthrough TherapyFirst in Class
Los Angeles, USA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Pulmonary Arterial Hypertension Pipeline Insight Research Report
Around 55+ key companies are developing therapies for Pulmonary Arterial Hypertension, among which the drug of Liquidia Technologies is in the advanced stage (Pre Registration)
DelveInsight’s “Pulmonary Arterial Hypertension (PAH) Pipeline Insight” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in the Pulmonary Arterial Hypertension pipeline landscapes. It comprises Pulmonary Arterial Hypertension pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Pulmonary Arterial Hypertension therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Pulmonary Arterial Hypertension pipeline products.
Some of the key takeaways from the Pulmonary Arterial Hypertension Pipeline Report
Get an overview of pipeline landscape @ Pulmonary Arterial Hypertension Clinical Trials Analysis
Pulmonary Arterial Hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure in the arteries of the lungs for no apparent reason.
Pulmonary Arterial Hypertension Emerging Drugs
Sotatercept is a first-in-class therapeutic fusion protein composed of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is in Phase III clinical trials for the treatment of PAH.
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company’s novel PRINT technology and engineered to enhance deep-lung delivery of treprostinil in PAH patients using a convenient, palm-sized dry powder inhaler. Liquidia resubmits New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH).
Gossamer Bio is developing Seralutinib (GB002) for the treatment of Pulmonary Arterial Hypertension. It is currently in the Phase II stage of development (NCT04456998). It acts as an inhibitor of Platelet-derived growth factor receptors, CSF1R, c-KIT.
Bial is developing Zamicastat for the treatment of Pulmonary Arterial Hypertension. It is currently in the Phase II stage of development (NCT04316143). It acts as an inhibitor of Dopamine beta-hydroxylase.
For further information, refer to the detailed report @ Pulmonary Arterial Hypertension Pipeline Therapeutics
Scope of Pulmonary Arterial Hypertension Pipeline Drug Insight
· Pulmonary Arterial Hypertension Therapies Late-stage (Phase III) · Pulmonary Arterial Hypertension Therapies Mid-stage (Phase II)· Pulmonary Arterial Hypertension Therapies Early-stage (Phase I) · Pulmonary Arterial Hypertension Preclinical stage and Discovery candidates · Discontinued and Inactive candidates
· Epoprostenol receptor agonistsEpoprostenol receptor agonists· Activin inhibitors· Platelet-derived growth factor receptor antagonists· Dopamine beta-hydroxylase inhibitors· Vasoactive intestinal peptide type II receptor agonistsVasoactive intestinal peptide type II receptor agonists· Angiogenesis inhibitors; Bcr-abl tyrosine kinase inhibitors · Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors· GalectinGalectin 3 inhibitors
· Peptides· Monoclonal antibodies· Small molecules · Proteins· Gene therapy
· Parenteral · Oral· Intravenous· Subcutaneous
· Monotherapy· Combination· Mono/Combination
Key Questions regarding Current Pulmonary Arterial Hypertension Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
Table of Contents
Get a customized pipeline report @ Pulmonary Arterial Hypertension Drugs Pipeline Report
Other Reports
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.